ETH-LAD, 6-
ethyl-6-nor-lysergic acid diethylamide is an analogue of
LSD. Its human psychopharmacology was first described by
Alexander Shulgin in the book
TiHKAL. ETH-LAD is a
psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[2] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding. The
true tryptamine counterpart of ETH-LAD is
MET, a simplified version of this structure.
Legality
On June 10, 2014, the UK
Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the
UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[3] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[4]
ETH-LAD is illegal in Switzerland as of December 2015.[5]
^Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5.
doi:
10.1021/jm00147a022.
PMID4032428.
Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5.
doi:
10.1021/jm00147a022.
PMID4032428.
Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9.
doi:
10.1007/BF02245940.
PMID7568626.
S2CID21484356.
Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994).
"Lysergamides Revisited"(PDF). NIDA Research Monograph 146: Hallucinogens: An Update. United States Department of Health and Human Services. p. 52. Archived from
the original(PDF) on 2015-07-23.
ETH-LAD, 6-
ethyl-6-nor-lysergic acid diethylamide is an analogue of
LSD. Its human psychopharmacology was first described by
Alexander Shulgin in the book
TiHKAL. ETH-LAD is a
psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[2] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding. The
true tryptamine counterpart of ETH-LAD is
MET, a simplified version of this structure.
Legality
On June 10, 2014, the UK
Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the
UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[3] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[4]
ETH-LAD is illegal in Switzerland as of December 2015.[5]
^Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5.
doi:
10.1021/jm00147a022.
PMID4032428.
Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5.
doi:
10.1021/jm00147a022.
PMID4032428.
Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9.
doi:
10.1007/BF02245940.
PMID7568626.
S2CID21484356.
Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994).
"Lysergamides Revisited"(PDF). NIDA Research Monograph 146: Hallucinogens: An Update. United States Department of Health and Human Services. p. 52. Archived from
the original(PDF) on 2015-07-23.